Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort

被引:63
|
作者
Shirai, Yuichiro
Yasuoka, Hidekata
Okano, Yutaka [2 ]
Takeuchi, Tsutomu
Satoh, Toru [3 ,4 ]
Kuwana, Masataka [1 ]
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol,Shinjuku Ku, Tokyo 1608582, Japan
[2] Kawasaki Municipal Hosp, Dept Internal Med, Kawasaki, Kanagawa, Japan
[3] Keio Univ, Sch Med, Dept Internal Med, Div Cardiol, Tokyo 1608582, Japan
[4] Kyorin Univ, Sch Med, Dept Cardiol, Tokyo, Japan
关键词
pulmonary arterial hypertension; mixed connective tissue disease; systemic lupus erythematosus; scleroderma; anti-U1RNP antibody; SYSTEMIC-SCLEROSIS; IMMUNOSUPPRESSIVE THERAPY; CLASSIFICATION; PREVALENCE; PREDICTORS; PROGNOSIS; DIAGNOSIS; BOSENTAN; CRITERIA; REGISTRY;
D O I
10.1093/rheumatology/kes140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To clarify the characteristics, survival and predictors of mortality in Japanese patients with pulmonary arterial hypertension (PAH) associated with CTD. Methods. This single-centre cohort study enrolled 70 consecutive patients with PAH-CTD who visited a tertiary referral centre in Japan between 1970 and 1990 (n = 30, historical group) and between 2000 and 2009 (n = 40, recent group). Baseline clinical features, haemodynamic parameters and ANA profiles were recorded. The Cox proportional hazards regression model was used to determine independent factors associated with an increased risk of mortality. Results. MCTD and SLE were the major underlying CTDs, comprising 43% and 29% of PAH patients respectively, whereas SSc was less common (19%). Anti-U1RNP antibody was the most prevalent ANA (61%). The cumulative survival rate was significantly better in the recent group in comparison with the historical group (76% vs 26% at 3 years; P < 0.001). When both groups were combined, World Health Organization functional class III or IV at diagnosis was identified as an independent predictor of mortality, whereas modern PAH drug use was associated with a favourable outcome. Conclusion. The major PAH-CTD population in Japan suffers from MCTD or SLE with anti-U1RNP antibody, in contrast to PAH-CTD patients in the USA and Europe. Modern PAH treatment has improved survival rates, but long-term outcomes are still unsatisfactory. Independent predictors of mortality indicate that early diagnosis and the prompt use of PAH drugs should improve survival.
引用
收藏
页码:1846 / 1854
页数:9
相关论文
共 50 条
  • [21] Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Disease-related Pulmonary Arterial Hypertension
    Ruiz-Cano, Maria J.
    Escribano, Pilar
    Alonso, Rafael
    Delgado, Juan
    Carreira, Patricia
    Velazquez, Teresa
    Gomez Sanchez, Miguel A.
    Saenz de la Calzada, Carlos
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (06): : 621 - 627
  • [22] PULMONARY HYPERTENSION AND OUTCOMES IN A SINGLE-CENTRE IPF COHORT
    Woods, D. R.
    Coker, R. K.
    Ind, P.
    Low, B.
    Hulston, G.
    Springett, J.
    Dos Santos, C.
    Hunt, C.
    Ward, K. H.
    THORAX, 2021, 76 : A161 - A162
  • [23] Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center
    Shirai, Yuichiro
    Yasuoka, Hidekata
    Takeuchi, Tsutomu
    Satoh, Toru
    Kuwana, Masataka
    MODERN RHEUMATOLOGY, 2013, 23 (06) : 1211 - 1220
  • [24] Treatment of Pulmonary Arterial Hypertension in Connective Tissue Disease
    Gruenig, Ekkehard
    DRUGS, 2012, 72 (08) : 1039 - 1056
  • [25] Pulmonary Arterial Hypertension Associated with Connective Tissue Disease
    Hatano, Masaru
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (10) : S124 - S124
  • [26] Retrospective cohort study of pulmonary arterial hypertension associated with connective tissue disease effect on patients' prognosis
    Huang, Jing
    An, Qi
    Shi, Hongyang
    Li, Cong
    Zhang, Wei
    Wang, Lei
    CLINICAL RHEUMATOLOGY, 2023, 42 (11) : 3131 - 3142
  • [27] Retrospective cohort study of pulmonary arterial hypertension associated with connective tissue disease effect on patients’ prognosis
    Jing Huang
    Qi An
    Hongyang Shi
    Cong Li
    Wei Zhang
    Lei Wang
    Clinical Rheumatology, 2023, 42 : 3131 - 3142
  • [28] Screening for Connective Tissue Disease in Pulmonary Arterial Hypertension
    Pagan, Ricardo J.
    Lee, Augustine S.
    Austin, Christopher O.
    Burger, Charles D.
    SOUTHERN MEDICAL JOURNAL, 2014, 107 (10) : 666 - 669
  • [29] Treatment of Pulmonary Arterial Hypertension in Connective Tissue Disease
    Ekkehard Grünig
    Drugs, 2012, 72 (8) : 1039 - 1056
  • [30] Survival and Predictors of Mortality In Australian Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
    Ngian, Gene-Siew
    Stevens, Wendy
    Byron, Jill
    Ai Tran
    Roddy, Janet E.
    Minson, Robert
    Hill, Catherine L.
    Chow, Ken
    Sahhar, Joanne
    Proudman, Susanna
    Nikpour, Mandana
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S332 - S332